Circulating soluble intercellular adhesion molecule-1 in lung cancer: A systematic review

Translational Lung Cancer Research

Volumn 1, Issue 1, 2012, Pages 36-44

  Gu, Xiaoling ^a   Ma, Chunyan ^a   Yuan, Dongmei ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Intercellular adhesion molecule; Lung cancer; Prognosis; Systematic review

Indexed keywords

EID: 84952795559     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.08.01     Document Type: Review

References (35)

1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.
2. Liotta LA, Stracke ML. Tumor invasion and metastases: biochemical mechanisms. Cancer Treat Res 1988;40:223-38.
3. Koyama S, Ebihara T, Fukao K. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 1992;118:609-14.
4. Johnson JP, Stade BG, Holzmann B, et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A 1989;86:641-4.
5. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw 2004;15:91-8.
6. Webb DS, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991;146:3682-6.
7. Braakman E, Goedegebuure PS, Vreugdenhil RJ, et al. ICAMmelanoma cells are relatively resistant to CD3-mediated T-cell lysis. Int J Cancer 1990;46:475-80.
8. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 1991;338:83-4.
9. Berendt AR, McDowall A, Craig AG, et al. The binding site on ICAM-1 for Plasmodium falciparum-infected erythrocytes overlaps, but is distinct from, the LFA-1-binding site. Cell 1992;68:71-81.
10. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-12.
11. Gho YS, Kleinman HK, Sosne G. Angiogenic activity of human soluble intercellular adhesion molecule-1. Cancer Res 1999;59:5128-32.
12. Gho YS, Kim PN, Li HC, et al. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 2001;61:4253-7.
13. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001;37:2392-7.
14. Nakata B, Hori T, Sunami T, et al.Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res 2000;6:1175-9.
15. Qian Q, Zhan P, Yu L, et al. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer. Clin Lung Cancer 2011;12:131-7.
16. Guney N, Soydinc HO, Derin D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol2008;25:194-200.
17. Grothey A, Heistermann P, Philippou S, et al. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer 1998;77:801-7.
18. Osaki T, Mitsudomi T, Yoshida Y, et al. Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with nonsmall cell lung cancer. Surg Oncol 1996;5:107-13.
19. Kamiyoshihara M, Kawashima O, Otani Y, et al. Clinical significance of the preoperative serum-soluble intercellular adhesion molecule-1 in non-small cell lung cancer. J Cardiovasc Surg (Torino) 2002;43:729-34.
20. Staal-van den Brekel AJ, Dentener MA, Schols AM, et al.Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13:2600-5.
21. De Vita F, Infusino S, Auriemma A, et al. Circulating levels of soluble intercellular adhesion molecule-1 in non-small cell lung cancer patients. Oncol Rep 1998;5:393-6.
22. Yurdakul AS, Han ER, Bukan N, et al. The Role of Serum Adhesion Molecules and Vascular Endothelial Growth Factor in Lung Cancer Patients. Turkiye Klinikleri Tip Bilimleri Dergisi 2010;30:1214-19.
23. Taguchi O, Gabazza EC, Kobayashi T, et al. Circulating intercellular adhesion molecule-1 in patients with lung cancer. Intern Med 1997;36:14-8.
24. Gogali A, Charalabopoulos K, Zampira I, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 2010;138:1173-9.
25. Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-12.
26. Shin HS, Jung CH, Park HD, et al. The relationship between the serum intercellular adhesion molecule-1 level and the prognosis of the disease in lung cancer. Korean J Intern Med 2004;19:48-52.
27. Staal-van den Brekel AJ, Schols AM, Dentener MA, et al. The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma. Br J Cancer 1997;76:1630-5.
28. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11.
29. Sprenger A, Schardt C, Rotsch M, et al. Soluble intercellular adhesion molecule-1 in patients with lung cancer and benign lung diseases. J Cancer Res Clin Oncol 1997;123:632-8.
30. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-smallcell lung cancer. J Clin Oncol 2010;28:193-201.
31. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med (Berl) 1996;74:13-33.
32. Leeuwenberg JF, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
33. Whiteman SC, Bianco A, Knight RA, et al. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem 2003;278:11954-61.
34. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34.
35. Rivoltini L, Cattoretti G, Arienti F, et al. The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer 1991;47:746-54.